Use of uptake intrinsic clearance from attached rat hepatocytes to predict hepatic clearance for poorly permeable compounds

We previously reported that the accuracy of clearance (CL) prediction could be differentiated by permeability. CL was drastically under-predicted by in vitro metabolic intrinsic clearance (CLint) for compounds with low permeability (<5 × 10−6 cm/s). We determined apparent uptake CLint by measuring initial disappearance from medium using attached rat hepatocytes and metabolic CLint by measuring parent depletion in suspended rat hepatocytes (cells and medium). Uptake and metabolic CLint were comparable for highly permeable metabolic marker compounds. In contrast, uptake CLint was 3- to 40-fold higher than metabolic CLint for rosuvastatin, bosentan, and 15 proprietary compounds, which had low permeability, suggesting that uptake could be a rate-determining step in hepatic elimination for these poorly permeable compounds. The prediction of hepatic CL was improved significantly when using uptake CLint for the compounds with low permeability. The average fold error was 2.2 and 6, as opposed to >11 and >47 by metabolic CLint, with and without applying a scaling factor of 4, respectively. Uptake CLint from attached hepatocytes can be used as an alternative approach to predict hepatic clearance and to understand the significance of hepatic uptake in elimination in an early drug discovery setting.

[1]  Aleksandra Galetin,et al.  Simultaneous Assessment of Uptake and Metabolism in Rat Hepatocytes: A Comprehensive Mechanistic Model , 2012, Journal of Pharmacology and Experimental Therapeutics.

[2]  A. Galetin,et al.  Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs , 2011, Drug Metabolism and Disposition.

[3]  E. van de Steeg,et al.  Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. , 2010, The Journal of clinical investigation.

[4]  April Chen,et al.  Relationship between Passive Permeability, Efflux, and Predictability of Clearance from In Vitro Metabolic Intrinsic Clearance , 2010, Drug Metabolism and Disposition.

[5]  Kazuya Maeda,et al.  Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans , 2010, Drug Metabolism and Disposition.

[6]  Zhiyang Zhao,et al.  Prediction of Vss from In Vitro Tissue-Binding Studies , 2010, Drug Metabolism and Disposition.

[7]  Thierry Lavé,et al.  Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[8]  Thierry Lavé,et al.  Prediction of Pharmacokinetic Profile of Valsartan in Humans Based on in vitro Uptake‐Transport Data , 2009, Chemistry & biodiversity.

[9]  Thierry Lavé,et al.  Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. , 2009, Molecular pharmaceutics.

[10]  K. Maeda,et al.  Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using in Vitro Uptake Experiments , 2009, Drug Metabolism and Disposition.

[11]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[12]  K. Maeda,et al.  Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.

[13]  S. Lowes,et al.  The Contribution of Organic Anion Transporters OAT1 and OAT3 to the Renal Uptake of Rosuvastatin , 2007, Journal of Pharmacology and Experimental Therapeutics.

[14]  B. Stieger,et al.  Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil , 2007, Drug Metabolism and Disposition.

[15]  Ken Grime,et al.  Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo , 2007, Drug Metabolism and Disposition.

[16]  C. Xia,et al.  Interactions of Cyclosporin A with Breast Cancer Resistance Protein , 2007, Drug Metabolism and Disposition.

[17]  J Brian Houston,et al.  Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance , 2007, Drug Metabolism and Disposition.

[18]  K. Maeda,et al.  DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 , 2006, Drug Metabolism and Disposition.

[19]  R. Kim,et al.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. , 2006, Gastroenterology.

[20]  R. Austin,et al.  A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.

[21]  Shelly X. Li,et al.  A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. , 2005, Rapid communications in mass spectrometry : RCM.

[22]  Kiyomi Ito,et al.  Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data from Hepatic Microsomes and Isolated Hepatocytes , 2004, Pharmaceutical Research.

[23]  Paul D. Martin,et al.  The effect of gemfibrozil on the pharmacokinetics of rosuvastatin , 2004, Clinical pharmacology and therapeutics.

[24]  Kim L. R. Brouwer,et al.  The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts , 2004, Pharmaceutical Research.

[25]  Yuichi Sugiyama,et al.  Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[26]  K. Higaki,et al.  Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[27]  K. Nezasa,et al.  Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[28]  F. Gonzalez,et al.  Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450 , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[30]  G R Wilkinson,et al.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[31]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[32]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[33]  E. Petzinger,et al.  Evidence for a saturable, energy-dependent and carrier-mediated uptake of oral antidiabetics into rat hepatocytes. , 1992, European journal of pharmacology.

[34]  K. Iwamoto,et al.  High capacity for pulmonary first‐pass elimination of propranolol in rats , 1987, The Journal of pharmacy and pharmacology.

[35]  P. Seglen.  Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. , 1973, Experimental cell research.

[36]  R. Evers,et al.  Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[37]  J Brian Houston,et al.  Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures. , 2005, Drug metabolism and disposition: the biological fate of chemicals.

[38]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[39]  P. Seglen.  Preparation of rat liver cells. II. Effects of ions and chelators on tissue dispersion. , 1973, Experimental cell research.